US12564590 — Combinations of menin inhibitors and CYP3A4 inhibitors and methods of use thereof
Method of Use · Assigned to Syndax Pharmaceuticals Inc · Expires 2042-12-18 · 17y remaining
What this patent protects
This patent protects combinations of menin inhibitors with CYP3A4 inhibitors for treating cancer and other diseases.
USPTO Abstract
The present invention is directed to combinations of menin inhibitors with one or more CYP3A4 inhibitors, pharmaceutical compositions thereof, and methods of treating cancer and other diseases mediated by the menin-HLL interaction. Accordingly, the present disclosure provides compounds, e.g., of Formula (II), which inhibit menin and are useful in the treatment of diseases mediated by the menin-MLL interaction in combination with a strong CYP3A4 inhibitor.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4045 |
— | revumenib-citrate |
U-4327 |
— | revumenib-citrate |
U-4327 |
— | revumenib-citrate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.